List view / Grid view
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
8 May 2015 | By Victoria White
WHO has called on scientists, national authorities and the media to follow best practices for disease names to minimise unnecessary negative effects...
8 May 2015 | By
The FDA has lifted the clinical hold on clinical studies of ND0612H and ND0612L, NeuroDerm's product candidates for the treatment of Parkinson’s disease...
8 May 2015 | By Victoria White
The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.
8 May 2015 | By Victoria White
Eleven Biotherapeutics presented clinical data for EBI-005 for dry eye disease and allergic conjunctivitis at the ARVO 2015 Annual Meeting...
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
8 May 2015 | By Victoria White
The Asia-Pacific treatment market for psoriasis will almost double in value, from $690 million in 2014 to $1.2 billion by 2021, representing a CAGR of 8.4%...
7 May 2015 | By Victoria White
Ohr Pharmaceutical presented the results from the Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet-AMD at ARVO...
7 May 2015 | By kdm communications
Operating capacity set to more than double in response to rising demand...
7 May 2015 | By Victoria White
The Bill & Melinda Gates Foundation are set to announce CHAMPS - a network of disease surveillance sites in developing countries...
7 May 2015 | By Victoria White
J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...
7 May 2015 | By Victoria White
Alexion Pharmaceuticals has announced that it is set to acquire Synageva BioPharma in a transaction valued at approximately $8.4 billion...
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
7 May 2015 | By
A 7-year study of a Nulojix regimen has demonstrated a significant relative risk reduction of death or transplant failure over a cyclosporine regimen...
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
